Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report

2019 Gupta, 2018, HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis, Lancet Infect Dis, 18, 346, 10.1016/S1473-3099(17)30702-8 Hamers, 2018, HIV drug resistance in low-income and middle-income countries, Lancet HIV, 5, e588, 10.1016/S2352-3018(18)30173-5 Napravnik, 2007, Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients, AIDS, 21, 825, 10.1097/QAD.0b013e32805e8764 Choi, 2014, The prevalence of antiretroviral multidrug resistance in highly active antiretroviral therapy-treated patients with HIV/AIDS between 2004 and 2009 in South Korea, J Clin Virol, 60, 154, 10.1016/j.jcv.2014.02.004 de Mulder, 2014, HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center paediatric cohort, Bronx, NY, USA, HIV Med, 15, 135, 10.1111/hiv.12089 Judd, 2017, Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe, HIV Med, 18, 171, 10.1111/hiv.12411 Magambo, 2014, The arrival of untreatable multidrug-resistant HIV-1 in sub-Saharan Africa, AIDS, 28, 1373, 10.1097/QAD.0000000000000216 Davy-Mendez, 2018, New antiretroviral agent use affects prevalence of HIV drug resistance in clinical care populations, AIDS, 32, 2593, 10.1097/QAD.0000000000001990 Kagan, 2019, Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017, AIDS Res Hum Retroviruses, 35, 698, 10.1089/aid.2019.0063 Armenia, 2020, HIV MDR is still a relevant issue despite its dramatic drop over the years, J Antimicrob Chemother, 10.1093/jac/dkz554 Fessel, 2011, The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment, Antiviral Res, 92, 484, 10.1016/j.antiviral.2011.09.010 Volpe, 2015, Five antiretroviral drug class-resistant HIV-1 in a treatment-naive patient successfully suppressed with optimized antiretroviral drug selection, J Int Assoc Provid AIDS Care, 14, 398, 10.1177/2325957415596229 Noguera-Julian, 2017, Next-generation human immunodeficiency virus sequencing for patient management and drug resistance surveillance, J Infect Dis, 216, S829, 10.1093/infdis/jix397 Turner, 2003, Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1, J Antimicrob Chemother, 53, 53, 10.1093/jac/dkh009 Cahn, 2018, Fostemsavir: a new CD4 attachment inhibitor, Curr Opin HIV AIDS, 13, 341, 10.1097/COH.0000000000000469 Emu, 2018, Phase 3 study of ibalizumab for multidrug-resistant HIV-1, N Engl J Med, 379, 645, 10.1056/NEJMoa1711460 Salie, 2016, Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA), Proc Natl Acad Sci USA, 113, 9274, 10.1073/pnas.1605223113 Carnes, 2018, Inhibitors of the HIV-1 capsid, a target of opportunity, Curr Opin HIV AIDS, 13, 359, 10.1097/COH.0000000000000472 Gardner, 2015, AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges, Nature, 519, 87, 10.1038/nature14264 Xu, 2017, Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques, Science, 358, 85, 10.1126/science.aan8630 Markowitz, 2005, Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report, Lancet, 365, 1031, 10.1016/S0140-6736(05)71139-9 Blick, 2007, The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1–infected patient, J Infect Dis, 195, 1250, 10.1086/512240 Knox, 2017, Multidrug-resistant HIV-1 infection despite preexposure prophylaxis, N Engl J Med, 376, 501, 10.1056/NEJMc1611639 Markowitz, 2017, Newly acquired infection with multidrug-resistant HIV-1 in a patient adherent to preexposure prophylaxis, J Acquir Immune Defic Syndr, 76, e104, 10.1097/QAI.0000000000001534 Colby, 2018, Acquisition of multidrug-resistant human immunodeficiency virus type 1 infection in a patient taking preexposure prophylaxis, Clin Infect Dis, 67, 962, 10.1093/cid/ciy321 Cong, 2007, The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions, J Virol, 81, 3037, 10.1128/JVI.02712-06 Castro, 2013, Persistence of HIV-1 transmitted drug resistance mutations, J Infect Dis, 208, 1459, 10.1093/infdis/jit345 Pou, 2014, Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing, Clin Infect Dis, 59, 578, 10.1093/cid/ciu287